{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:30Z","timestamp":1793120070658,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["T4-CN-02"],"award-info":[{"award-number":["T4-CN-02"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126932","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T22:45:21Z","timestamp":1740869121000},"page":"126932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices"],"prefix":"10.1016","volume":"53","author":[{"given":"Sara","family":"Tengattini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Bavaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Temporini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredano","family":"Pollegioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Terreni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Piubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126932_bb0005","first-page":"102","article-title":"A five year incidence trend analysis of tuberculosis (TB) and HIV\/AIDs co-infection at Bo government hospital, southern Sierra Leone","volume":"3","author":"Babawo","year":"2020","journal-title":"J Public Health Dis Prev"},{"key":"10.1016\/j.vaccine.2025.126932_bb0010","series-title":"Tuberculosis control in migrating population, 1\u201310","article-title":"Overview of tuberculosis","author":"Yu","year":"2020"},{"key":"10.1016\/j.vaccine.2025.126932_bb0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tube.2016.03.006","article-title":"Current perspective in tuberculosis vaccine development for high TB endemic regions","volume":"98","author":"Husain","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.vaccine.2025.126932_bb0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","article-title":"Immune responses to Bacillus Calmette-Gu\u00e9rin vaccination: why do they fail to protect against mycobacterium tuberculosis?","volume":"8","author":"Moliva","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG world atlas: A database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.126932_bb0030","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1016\/j.vaccine.2015.08.033","article-title":"Prospects in Mycobacterium bovis Bacille Calmette et Gu\u00e9rin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?","volume":"33","author":"Moliva","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126932_bb0035","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126932_bb0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ije\/dyx141","article-title":"The duration of protection of school-aged BCG vaccination in England: A population-based case-control study","volume":"47","author":"Mangtani","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tube.2011.12.003","article-title":"BCG: myths, realities, and the need for alternative vaccine strategies","volume":"92","author":"McShane","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2025.126932_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0015-2016","article-title":"Clinical testing of tuberculosis vaccine candidates","volume":"4","author":"Hatherill","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2025.126932_bb0055","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","article-title":"Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial","volume":"29","author":"Barreto","year":"2011","journal-title":"Vaccine"},{"issue":"414027","key":"10.1016\/j.vaccine.2025.126932_bb0060","article-title":"Successive intramuscular boosting with IFN-alpha protects Mycobacterium bovis BCG-vaccinated mice against M lepraemurium infection","volume":"2015","author":"Guerrero","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2025.126932_bb0065","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fimmu.2017.00556","article-title":"What we have learned and what we have missed in tuberculosis pathophysiology for a new vaccine design: searching for the \u201cpink swan\u201d","volume":"8","author":"Cardona","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0070","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fimmu.2018.00308","article-title":"Vaccines for leprosy and tuberculosis: opportunities for shared research, development, and application","volume":"9","author":"Coppola","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.micpath.2017.08.040","article-title":"Antigen 85 complex as a powerful mycobacterium tuberculosis immunogene: biology, immune-pathogenicity, applications in diagnosis, and vaccine design","volume":"112","author":"Babaki","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2025.126932_bb0080","first-page":"255","article-title":"DNA based vaccines against mycobacterium tuberculosis: recent Progress in vaccine development and delivery system","volume":"17","author":"Mobed","year":"2020","journal-title":"Iran J Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0085","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1074\/jbc.M111.298687","article-title":"Novel mycobacteria antigen 85 complex binding motif on fibronectin","volume":"287","author":"Kuo","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/iai.65.2.676-684.1997","article-title":"Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Gu\u00e9rin-infected mice","volume":"65","author":"Denis","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126932_bb0095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fimmu.2014.00321","article-title":"The immunodominant T-cell epitopes of the mycolyl-transferases of the antigen 85 complex of M. Tuberculosis","volume":"5","author":"Huygen","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1101\/gr166401","article-title":"Comparing genomes within the species mycobacterium tuberculosis","volume":"11","author":"Kato-Maeda","year":"2001","journal-title":"Genome Res"},{"key":"10.1016\/j.vaccine.2025.126932_bb0105","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1128\/IAI.70.10.5446-5453.2002","article-title":"Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family","volume":"70","author":"Skj\u00f8t","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126932_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/jmbi.2001.4461","article-title":"An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the mycobacterium tuberculosis 30 kDa major secretory protein (antigen 85B), a mycolyl transferase","volume":"307","author":"Anderson","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0115","doi-asserted-by":"crossref","first-page":"29993","DOI":"10.1074\/jbc.M111.248732","article-title":"Solution structure of the mycobacterium tuberculosis EsxG\u00b7EsxH complex: functional implications and comparisons with other M. Tuberculosis Esx family complexes","volume":"286","author":"Ilghari","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-024-00834-y","article-title":"Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development","volume":"9","author":"Chugh","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.126932_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41541-023-00750-7","article-title":"Key advances in vaccine development for tuberculosis-success and challenges","volume":"8","author":"Lai","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.126932_bb0130","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.2174\/0929867326666181126112124","article-title":"Novel vaccine candidates against tuberculosis","volume":"27","author":"Li","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/IAI.68.1.233-238.2000","article-title":"Enhanced production of recombinant mycobacterium tuberculosis antigens in Escherichia coli by replacement of low-usage codons","volume":"68","author":"Lakey","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126932_bb0140","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.4049\/jimmunol.174.10.6332","article-title":"Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy","volume":"174","author":"Dietrich","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/IAI.68.1.214-220.2000","article-title":"Comparative evaluation of low-molecular-mass proteins from mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens","volume":"68","author":"Skj\u00f8t","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126932_bb0150","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11095-009-9995-y","article-title":"Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against mycobacterium tuberculosis","volume":"27","author":"Shi","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2025.126932_bb0155","first-page":"187","article-title":"A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. Coli cytoplasm","volume":"11","author":"LaVallie","year":"1993","journal-title":"Biotechnology"},{"key":"10.1016\/j.vaccine.2025.126932_bb0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1475-2859-12-115","article-title":"Optimizing Escherichia coli as a protein expression platform to produce mycobacterium tuberculosis immunogenic proteins","volume":"12","author":"Piubelli","year":"2013","journal-title":"Microb Cell Factories"},{"key":"10.1016\/j.vaccine.2025.126932_bb0165","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3390\/molecules22071081","article-title":"Glycosylation of recombinant antigenic proteins from mycobacterium tuberculosis: In silico prediction of protein epitopes and ex vivo biological evaluation of new semi-synthetic glycoconjugates","volume":"22","author":"Bavaro","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.vaccine.2025.126932_bb0170","doi-asserted-by":"crossref","first-page":"23171","DOI":"10.1039\/C8RA03535K","article-title":"Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against mycobacterium tuberculosis","volume":"8","author":"Rinaldi","year":"2018","journal-title":"RSC Adv"},{"key":"10.1016\/j.vaccine.2025.126932_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005229","article-title":"Overexpression of a mycobacterium ulcerans Ag85B-EsxH fusion protein in recombinant BCG improves experimental Buruli ulcer vaccine efficacy","volume":"10","author":"Hart","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.126932_bb0180","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/eji.201847988","article-title":"MHC-restricted Ag85B-specific CD8+ T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice","volume":"49","author":"Komine-Aizawa","year":"2019","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0185","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/vaccines9111260","article-title":"Recombinant BCG-prime and DNA-boost immunization confers mice with enhanced protection against mycobacterium kansasii","volume":"9","author":"Komine-Aizawa","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.126932_bb0190","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/ijms24020966","article-title":"The induction of antigen 85B-specific CD8+ T cells by recombinant BCG protects against mycobacterial infection in mice","volume":"24","author":"Komine-Aizawa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2025.126932_bb0195","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3389\/fimmu.2019.01588","article-title":"Inactivated lactobacillus plantarum carrying a surface-displayed Ag85B-ESAT-6 fusion antigen as a booster vaccine against mycobacterium tuberculosis infection","volume":"10","author":"Kuczkowska","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0200","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/imcb.12462","article-title":"Intranasal immunization with Ag85B peptide 25 displayed on Lactococcus lactis using the PilVax platform induces antigen-specific B- and T-cell responses","volume":"99","author":"Blanchett","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0205","article-title":"Comparison of the immunogenic properties of Lactiplantibacillus plantarum carrying the mycobacteria Ag85B-ESAT-6 antigen at various cellular localizations","volume":"13","author":"Will","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.imlet.2017.07.007","article-title":"Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis","volume":"190","author":"Kou","year":"2017","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2025.126932_bb0215","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4014\/jmb.1712.12064","article-title":"Performance of homologous and heterologous prime-boost immunization regimens of recombinant adenovirus and modified vaccinia virus Ankara expressing an Ag85B-TB10.4 fusion protein against mycobacterium tuberculosis","volume":"28","author":"Kou","year":"2018","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.micpath.2019.01.045","article-title":"Mycobacterium tuberculosis Ag85b:hfc\u03b31 recombinant fusion protein as a selective receptor-dependent delivery system for antigen presentation","volume":"129","author":"Babaki","year":"2019","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2025.126932_bb0225","first-page":"3034","article-title":"Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice","volume":"15","author":"Huang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.vaccine.2025.126932_bb0230","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12033-021-00307-w","article-title":"Alfalfa plants (Medicago sativa L.) expressing the 85B (MAP1609c) antigen of Mycobacterium avium subsp. paratuberculosis elicit long-lasting immunity in mice","volume":"63","author":"Monreal-Escalante","year":"2021","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13062-024-00454-5","article-title":"Effect of glycosylation on the affinity of the MTB protein Ag85B for specific antibodies: towards the design of a dual-acting vaccine against tuberculosis","volume":"19","author":"Bernardini","year":"2024","journal-title":"Biol Direct"},{"key":"10.1016\/j.vaccine.2025.126932_bb0240","doi-asserted-by":"crossref","first-page":"8498","DOI":"10.1002\/anie.201003810","article-title":"Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue","volume":"49","author":"Hoffmann-R\u00f6der","year":"2010","journal-title":"Angew Chem Int Ed Eng"},{"key":"10.1016\/j.vaccine.2025.126932_bb0245","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/07328303.2012.659364","article-title":"Recent development in carbohydrate based anti-cancer vaccines","volume":"31","author":"Yin","year":"2012","journal-title":"J Carbohydr Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0250","doi-asserted-by":"crossref","first-page":"15603","DOI":"10.1021\/acs.chemrev.1c01032","article-title":"Glycoconjugates: synthesis, functional studies, and therapeutic developments","volume":"122","author":"Shivatare","year":"2022","journal-title":"Chem Rev"},{"key":"10.1016\/j.vaccine.2025.126932_bb0255","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/cr0004310","article-title":"Synthesis of glycoproteins","volume":"102","author":"Davis","year":"2002","journal-title":"Chem Rev"},{"key":"10.1016\/j.vaccine.2025.126932_bb0260","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2174\/1385272819666150810204736","article-title":"From new diagnostic targets to recombinant proteins and semi-synthetic protein-based vaccines","volume":"20","author":"Bavaro","year":"2016","journal-title":"Curr Org Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0265","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.addr.2021.01.021","article-title":"Chemical (neo)glycosylation of biological drugs","volume":"171","author":"Walther","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2025.126932_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006250","article-title":"Enhanced control of mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine","volume":"13","author":"Prados-Rosales","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.126932_bb0275","doi-asserted-by":"crossref","first-page":"56455","DOI":"10.1039\/C4RA11131A","article-title":"Chemoenzymatic synthesis of neoglycoproteins driven by the assessment of protein surface reactivity","volume":"4","author":"Bavaro","year":"2014","journal-title":"RSC Adv"},{"key":"10.1016\/j.vaccine.2025.126932_bb0280","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/ejoc.201901915","article-title":"A concise synthesis of oligosaccharides derived from lipoarabinomannan (LAM) with glycosyl donors having a nonparticipating group at C2","volume":"2020","author":"Li","year":"2020","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112578","article-title":"Chemoenzymatic synthesis of arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis","volume":"204","author":"Li","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0290","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/pharmaceutics15051321","article-title":"Glycovaccine design: optimization of model and antitubercular carrier glycosylation via disuccinimidyl homobifunctional linker","volume":"15","author":"Tengattini","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.126932_bb0295","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.1016\/j.bmc.2017.09.027","article-title":"Conjugation of the CRM197-inulin conjugate significantly increases the immunogenicity of mycobacterium tuberculosis CFP10-TB10.4 fusion protein","volume":"25","author":"Hu","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0300","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1021\/acs.molpharmaceut.6b00138","article-title":"Conjugation with an inulin-chitosan adjuvant markedly improves the immunogenicity of mycobacterium tuberculosis CFP10-TB10.4 fusion protein","volume":"13","author":"Yu","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2025.126932_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejpb.2022.02.011","article-title":"Conjugation with loxoribine and mannan improves the immunogenicity of mycobacterium tuberculosis CFP10-TB10.4 fusion protein","volume":"172","author":"Yu","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2025.126932_bb0310","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1021\/acs.jmedchem.9b00832","article-title":"Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against mycobacterium tuberculosis","volume":"62","author":"Ashhurst","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0315","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3389\/fimmu.2019.01349","article-title":"Immunization with mycobacterium tuberculosis antigens encapsulated in phosphatidylserine liposomes improves protection afforded by BCG","volume":"10","author":"Diogo","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03611-22","article-title":"A MAPS vaccine induces multipronged systemic and tissue-resident cellular responses and protects mice against mycobacterium tuberculosis","volume":"14","author":"O\u2019Hara","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.126932_bb0325","doi-asserted-by":"crossref","first-page":"13564","DOI":"10.1073\/pnas.1307228110","article-title":"Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.126932_bb0335","article-title":"Fusion peptide constructs from antigens of M. Tuberculosis producing high T-cell mediated immune response","volume":"17, e0271126","author":"Arif","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126932_bb0340","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1096\/fj.201802501RR","article-title":"Innovative antigen carrier system for the development of tuberculosis vaccines","volume":"33","author":"Chen","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2025.126932_bb0345","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3390\/nano11082060","article-title":"Particulate mycobacterial vaccines induce protective immunity against tuberculosis in mice","volume":"11","author":"Chen","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.vaccine.2025.126932_bb0350","first-page":"998","article-title":"Cloning, expression and T cell epitope prediction of fbpA and fbpB genes of mycobacterium tuberculosis clinical isolates","volume":"9","author":"Fihiruddin","year":"2020","journal-title":"JMBFS"},{"key":"10.1016\/j.vaccine.2025.126932_bb0355","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126932_bb0360","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1016\/j.vaccine.2023.04.003","article-title":"Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates","volume":"41","author":"Wang","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126932_bb0365","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.tube.2016.09.016","article-title":"Recombinant Bacillus subtilis spores for the delivery of mycobacterium tuberculosis Ag85B-CFP10 secretory antigens","volume":"101S","author":"Das","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2025.126932_bb0370","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpba.2018.05.005","article-title":"Enterokinase monolithic bioreactor as an efficient tool for biopharmaceuticals preparation: on-line cleavage of fusion proteins and analytical characterization of released products","volume":"157","author":"Tengattini","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.vaccine.2025.126932_bb0375","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00216-016-0071-2","article-title":"Erratum to: monitoring antigenic protein integrity during glycoconjugate vaccine synthesis using capillary electrophoresis-mass spectrometry","volume":"409","author":"Tengattini","year":"2017","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0380","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.aca.2017.05.020","article-title":"Hydrophilic interaction liquid chromatography-mass spectrometry as a new tool for the characterization of intact semi-synthetic glycoproteins","volume":"981","author":"Tengattini","year":"2017","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.vaccine.2025.126932_bb0385","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acs.bioconjchem.7b00131","article-title":"Conjugation reaction with 8-arm PEG markedly improves the immunogenicity of mycobacterium tuberculosis CFP10-TB10.4 fusion protein","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0390","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpba.2017.03.052","article-title":"Application of a rapid HILIC-UV method for synthesis optimization and stability studies of immunogenic neo-glycoconjugates","volume":"144","author":"Rinaldi","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.vaccine.2025.126932_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080579","article-title":"ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination","volume":"8","author":"Hoang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126932_bb0400","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1038\/s41598-019-47657-9","article-title":"Ensilication improves the thermal stability of the tuberculosis antigen Ag85b and an Sbi-Ag85b vaccine conjugate","volume":"9","author":"Wahid","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126932_bb0405","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chroma.2014.09.041","article-title":"Liquid chromatography\u2013mass spectrometry structural characterization of neo glycoproteins aiding the rational design and synthesis of a novel glycovaccine for protection against tuberculosis","volume":"1367","author":"Temporini","year":"2014","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.vaccine.2025.126932_bb0410","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpba.2018.05.048","article-title":"Tuberculosis vaccine candidate: characterization of H4-IC31 formulation and H4 antigen conformation","volume":"157","author":"Deshmukh","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.vaccine.2025.126932_bb0415","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00216-018-1466-z","article-title":"Epitope and affinity determination of recombinant mycobacterium tuberculosis Ag85B antigen towards anti-Ag85 antibodies using proteolytic affinity-mass spectrometry and biosensor analysis","volume":"411","author":"Rinaldi","year":"2019","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.vaccine.2025.126932_bb0420","article-title":"A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice","volume":"2","author":"Khan","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2025.126932_bb0425","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3390\/vaccines9111273","article-title":"Enhancement of the local CD8+ T-cellular immune response to mycobacterium tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10.4 and HspX antigens","volume":"9","author":"Vasilyev","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.126932_bb0430","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/vaccines9040394","article-title":"Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against mycobacterium tuberculosis in mice and Guinea pigs","volume":"9","author":"Sergeeva","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.126932_bb0435","doi-asserted-by":"crossref","first-page":"1127515","DOI":"10.3389\/fimmu.2023.1127515","article-title":"Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice","volume":"14","author":"Kirk","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0440","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s42003-022-04345-1","article-title":"Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL\/6 and BALB\/c mice and Guinea pigs against mycobacterium tuberculosis challenge","volume":"5","author":"Jia","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.vaccine.2025.126932_bb0445","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00687-22","article-title":"Listeria-vectored multiantigenic tuberculosis vaccine enhances protective immunity against aerosol challenge with virulent mycobacterium tuberculosis in BCG-immunized C57BL\/6 and BALB\/c mice","volume":"13","author":"Jia","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.126932_bb0450","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.tube.2019.04.009","article-title":"Enhanced delivery of mycobacterium tuberculosis antigens to antigen presenting cells using RVG peptide","volume":"116S","author":"Garnica","year":"2019","journal-title":"Tuberculosis (Edinb)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T02:24:58Z","timestamp":1745115898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":89,"alternative-id":["S0264410X25002294"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126932","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126932"}}